Nuvo Research Inc (NRIFF) 4.7350 $NRIFF
Chrysler Group Reports Full-Year 2013 Net Income of $2.8 Billion, Including a $962 Million Non-Cash Tax Benefit
PR Newswire - Wed Jan 29, 4:26AM CST
-- Chrysler Group LLC's full-year net income was $2.8 billion, including a $962 million non-cash tax benefit related to the release of valuation allowances on deferred tax assets; full-year 2012 net income was $1.7 billion
NRI.TO: 5.35 (+0.03)
Nuvo Research announces notice of Intention to Grant a European Patent for PENNSAID® 2%
PR Newswire - Thu May 09, 6:30AM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that the European Patent Office has issued a notice of Intention to Grant a European Patent that provides protection for the Company's PENNSAID® 2% product. Upon grant by the European Patent Office, the patent can be officially validated in over 37 European countries.
NRI.TO: 5.35 (+0.03)
Nuvo Research to Complete Share Consolidation
PR Newswire - Tue May 07, 6:30AM CDT
Nuvo Research Inc. (TSX: NRI) (the "Company" or "Nuvo"
, a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that it will proceed with its proposed share consolidation (the "Consolidation" , as approved by the shareholders of Nuvo at the annual and special meeting held on May 15, 2012, on the basis of 65 pre-Consolidation common shares for one (1) post-Consolidation common share.
NRI.TO: 5.35 (+0.03)
Nuvo Research announces 2013 First Quarter Results
PR Newswire - Wed May 01, 4:00PM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the first quarter ended March 31, 2013.
NRI.TO: 5.35 (+0.03)
Nuvo Research Announces European Launch of Pliaglis(R) by Galderma
Business Wire - Tue Apr 23, 6:45AM CDT
Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology. Marketing licenses have been issued in 14 of the 16 European countries which are listed in the European Marketing Application for Pliaglis.
NRI.TO: 5.35 (+0.03)
Nuvo Research announces European launch of Pliaglis® by Galderma
PR Newswire - Tue Apr 23, 6:30AM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology. Marketing licenses have been issued in 14 of the 16 European countries which are listed in the European Marketing Application for Pliaglis.
NRI.TO: 5.35 (+0.03)
Acute Pain - Pipeline Review, H1 2013
M2 - Fri Apr 05, 7:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gdw5kx/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2013" report to their offering. 'Acute Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Pain. Acute Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Acute Pain. - Identi
ACRX: 6.61 (-0.24), PFE: 28.30 (+0.02), BMY: 51.84 (-0.11), NKTR: 12.67 (+0.03), PCRX: 101.30 (+0.45), ARRY: 3.37 (-0.11), PTIE: 4.12 (-0.08)
Nuvo Research announces 2012 Fourth Quarter & Year-End Results
PR Newswire - Wed Mar 27, 4:00PM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the fourth quarter and year ended December 31, 2012.
NRI.TO: 5.35 (+0.03)
Nuvo Research provides additional information regarding Pennsaid 2%
CNW Group - Mon Mar 18, 6:30AM CDT
Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that a Question and Answer document has been posted on its website to provide additional information to Nuvo shareholders regarding the regulatory status of Pennsaid 2% in the United States. Follow this link to access the document - Pennsaid 2% Q&A.
NRI.TO: 5.35 (+0.03)
Nuvo Research announces U.S. launch of Pliaglis® by Galderma
CNW Group - Mon Mar 11, 6:30AM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Laboratories, L.P., the U.S. affiliate of Galderma Pharma, S.A. (Galderma), today announced the U.S. launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.
NRI.TO: 5.35 (+0.03)
Nuvo Research announces FDA response to PENNSAID® 2% NDA
PR Newswire - Tue Mar 05, 6:00AM CST
Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that its U.S. licensing partner, Mallinckrodt, the Pharmaceuticals Business of Covidien (NYSE:COV), has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following the review of Mallinckrodt's New Drug Application (NDA) for diclofenac sodium topical solution, 2% w/w (PENNSAID 2%).
NRI.TO: 5.35 (+0.03), COV: 87.41 (-1.84)
Nuvo Research announces settlement agreement with Apotex in PENNSAID® generic litigation
CNW Group - Tue Jan 29, 6:30AM CST
Nuvo Research Inc. (Nuvo) (TSX: NRI) announced today that it has entered into a settlement agreement with Apotex Inc. and Apotex Corp. (together Apotex) respecting patent infringement litigation brought by Nuvo and Nuvo's U.S. licensing partner, Mallinckrodt Inc. (Mallinckrodt), in response to Apotex's filing of an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w (PENNSAID).
NRI.TO: 5.35 (+0.03)
Chrysler Group Reports Full-Year 2013 Net Income of $2.8 Billion, Including a $962 Million Non-Cash Tax Benefit
PR Newswire - Wed Jan 29, 4:26AM CST
-- Chrysler Group LLC's full-year net income was $2.8 billion, including a $962 million non-cash tax benefit related to the release of valuation allowances on deferred tax assets; full-year 2012 net income was $1.7 billion
NRI.TO: 5.35 (+0.03)
Nuvo Research announces notice of Intention to Grant a European Patent for PENNSAID® 2%
PR Newswire - Thu May 09, 6:30AM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that the European Patent Office has issued a notice of Intention to Grant a European Patent that provides protection for the Company's PENNSAID® 2% product. Upon grant by the European Patent Office, the patent can be officially validated in over 37 European countries.
NRI.TO: 5.35 (+0.03)
Nuvo Research to Complete Share Consolidation
PR Newswire - Tue May 07, 6:30AM CDT
Nuvo Research Inc. (TSX: NRI) (the "Company" or "Nuvo"
, a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that it will proceed with its proposed share consolidation (the "Consolidation" , as approved by the shareholders of Nuvo at the annual and special meeting held on May 15, 2012, on the basis of 65 pre-Consolidation common shares for one (1) post-Consolidation common share. NRI.TO: 5.35 (+0.03)
Nuvo Research announces 2013 First Quarter Results
PR Newswire - Wed May 01, 4:00PM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the first quarter ended March 31, 2013.
NRI.TO: 5.35 (+0.03)
Nuvo Research Announces European Launch of Pliaglis(R) by Galderma
Business Wire - Tue Apr 23, 6:45AM CDT
Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology. Marketing licenses have been issued in 14 of the 16 European countries which are listed in the European Marketing Application for Pliaglis.
NRI.TO: 5.35 (+0.03)
Nuvo Research announces European launch of Pliaglis® by Galderma
PR Newswire - Tue Apr 23, 6:30AM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology. Marketing licenses have been issued in 14 of the 16 European countries which are listed in the European Marketing Application for Pliaglis.
NRI.TO: 5.35 (+0.03)
Acute Pain - Pipeline Review, H1 2013
M2 - Fri Apr 05, 7:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gdw5kx/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2013" report to their offering. 'Acute Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Pain. Acute Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Acute Pain. - Identi
ACRX: 6.61 (-0.24), PFE: 28.30 (+0.02), BMY: 51.84 (-0.11), NKTR: 12.67 (+0.03), PCRX: 101.30 (+0.45), ARRY: 3.37 (-0.11), PTIE: 4.12 (-0.08)
Nuvo Research announces 2012 Fourth Quarter & Year-End Results
PR Newswire - Wed Mar 27, 4:00PM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the fourth quarter and year ended December 31, 2012.
NRI.TO: 5.35 (+0.03)
Nuvo Research provides additional information regarding Pennsaid 2%
CNW Group - Mon Mar 18, 6:30AM CDT
Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that a Question and Answer document has been posted on its website to provide additional information to Nuvo shareholders regarding the regulatory status of Pennsaid 2% in the United States. Follow this link to access the document - Pennsaid 2% Q&A.
NRI.TO: 5.35 (+0.03)
Nuvo Research announces U.S. launch of Pliaglis® by Galderma
CNW Group - Mon Mar 11, 6:30AM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Laboratories, L.P., the U.S. affiliate of Galderma Pharma, S.A. (Galderma), today announced the U.S. launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.
NRI.TO: 5.35 (+0.03)
Nuvo Research announces FDA response to PENNSAID® 2% NDA
PR Newswire - Tue Mar 05, 6:00AM CST
Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that its U.S. licensing partner, Mallinckrodt, the Pharmaceuticals Business of Covidien (NYSE:COV), has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following the review of Mallinckrodt's New Drug Application (NDA) for diclofenac sodium topical solution, 2% w/w (PENNSAID 2%).
NRI.TO: 5.35 (+0.03), COV: 87.41 (-1.84)
Nuvo Research announces settlement agreement with Apotex in PENNSAID® generic litigation
CNW Group - Tue Jan 29, 6:30AM CST
Nuvo Research Inc. (Nuvo) (TSX: NRI) announced today that it has entered into a settlement agreement with Apotex Inc. and Apotex Corp. (together Apotex) respecting patent infringement litigation brought by Nuvo and Nuvo's U.S. licensing partner, Mallinckrodt Inc. (Mallinckrodt), in response to Apotex's filing of an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w (PENNSAID).
NRI.TO: 5.35 (+0.03)
